Tenofovir is a potent antiviral compound primarily used in the treatment of HIV and hepatitis B infections. As a nucleotide reverse transcriptase inhibitor (NRTI), it works by interfering with the replication of viral DNA, thereby reducing the viral load in patients. Its unique structure allows for effective incorporation into viral DNA, making it a critical component of combination therapy regimens. Tenofovir is recognized for its favorable safety profile and has been extensively studied, demonstrating significant efficacy in clinical trials.

In addition to its primary applications in antiviral therapy, Tenofovir is also being explored for potential use in pre-exposure prophylaxis (PrEP) to prevent HIV transmission in high-risk populations. Its versatility and effectiveness make it a valuable asset in both clinical and research settings, providing healthcare professionals with a reliable option for managing viral infections. Researchers continue to investigate its potential in various therapeutic contexts, underscoring its relevance in modern medicine.